Lexington-based clinical stage biotech firm Pulmatrix, Inc. is pioneering inhaled therapies for respiratory and other diseases with unmet medical needs in the US. The company is leveraging its innovative inhaled small particles easily respirable and emitted (iSPERSE) technology to develop products that can deliver small or large molecule drugs to the lungs through inhalation for both local and systemic applications. Its product pipeline includes PUR1800, a narrow spectrum kinase inhibitor that has completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900, a treatment for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. Pulmatrix has a license agreement with RespiVert Ltd. to access a portfolio of kinase inhibitor drug candidates, and a development and commercialization agreement with Cipla Technologies LLC for PUR1900. Founded in 2003, Pulmatrix is committed to finding innovative ways to tackle respiratory diseases with significant unmet medical needs.